biote (US:BTMD)2025-11-05 21:08Financial Performance - Total revenue for Q3 2025 was $48.0 million, a decrease of 6.7% from $51.4 million in the prior year[5]. - Total revenue for Q3 2025 was $47,956,000, a decrease of 8.3% compared to $51,384,000 in Q3 2024[27]. - Product revenue decreased to $46,953,000 in Q3 2025 from $49,806,000 in Q3 2024, representing a decline of 5.7%[27]. - Net income was $9.2 million, with diluted earnings per share of $0.22, compared to $12.7 million and $0.33 in the prior year[7]. - Net income for Q3 2025 was $9,216,000, a decrease of 27.4% from $12,657,000 in Q3 2024[31]. - Net income attributable to Biote Corp. stockholders for Q3 2025 was $8,188,000, down from $10,702,000 in Q3 2024, a decrease of 23.5%[27]. - Adjusted EBITDA was $12.9 million, a decrease of 20.5% from $16.2 million, with an Adjusted EBITDA margin of 26.9%[8]. - Adjusted EBITDA for Q3 2025 was $12,881,000, representing a margin of 26.9%, compared to 31.5% in Q3 2024[31]. - Adjusted EBITDA for the nine months ended September 30, 2025 was $41,807,000, slightly down from $43,102,000 in 2024[31]. - Operating income decreased by 32.1% to $8.3 million due to reduced gross profit and higher operating expenses[6]. Revenue Breakdown - Procedure revenue declined by 10.4%, while dietary supplements revenue grew by 8.4%[5]. - The annual provider conference was shifted to Q3 2025, impacting operating expenses and procedure revenue[6][8]. Cash Flow and Assets - Cash and cash equivalents decreased to $28,048,000 as of September 30, 2025, from $39,342,000 at the end of 2024, a decline of 28.6%[28]. - Total assets decreased to $111,324,000 as of September 30, 2025, down from $122,370,000 at the end of 2024, a reduction of 9.0%[25]. - Total liabilities decreased to $176,791,000 as of September 30, 2025, compared to $224,570,000 at the end of 2024, a decrease of 21.3%[25]. - Operating cash flow for the nine months ended September 30, 2025, was $27,625,000, down from $32,875,000 in the same period of 2024, a decline of 16.9%[28]. Expenses - Selling, general and administrative expenses increased to $26,151,000 in Q3 2025 from $23,922,000 in Q3 2024, an increase of 9.6%[27]. - Interest expense for Q3 2025 was $2,733,000, a decrease from $3,542,000 in Q3 2024[31]. - Litigation expenses for Q3 2025 totaled $323,000, compared to $401,000 in Q3 2024[31]. - The company incurred $586,000 in restructuring-related expenses for the nine months ended September 30, 2025[31]. Shareholder Actions - Biote repurchased approximately one million shares of Class A common stock in Q3 2025[11]. - The company reiterated its 2025 financial outlook, forecasting revenue above $190 million and Adjusted EBITDA above $50 million[12]. - Biote continues to focus on strategic priorities to drive sustainable growth and enhance shareholder value[11].